Locoid Crelo (hydrocortisone butyrate) is commonly used in situations involving symptoms related to inflammatory or irritative states in adults and may be part of symptomatic management for Atopic Dermatitis in relevant pediatric patient groups. The medication is applied across therapeutic domains where short-term symptom management is appropriate, notably in conditions presenting with acute symptoms such as excessive redness, localized swelling, and severe itching (pruritus).

This medication is relevant in contexts marked by increased discomfort, helping to address symptom clusters that may become intense or disruptive during flare-ups of conditions like Eczema and various forms of Dermatitis. Offering symptomatic relief is intended to help patients cope more steadily with difficult episodes and supports the patient during episodes of heightened discomfort. The emulsion is also relevant when supportive symptom management is appropriate for difficult areas, such as the scalp or other hairy parts of the skin.

---

Quick Fact: Symptom Management
Primary Symptom Focus	Reducing symptoms related to inflammatory or irritative states and severe pruritus.
Common Clinical Context	Applied in scenarios where short-term symptomatic assistance is needed during acute episodes.
Patient Benefit	Contributes to easing the overall symptom load and helps improve day-to-day comfort.

Regulatory References

1. NIH DailyMed Overview

Eligibility scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and pediatric patients 3 months of age and older [Source 1.1, 1.2].
Populations for whom use is not recommended	Infants younger than 3 months of age (safety and efficacy not established) [Source 1.2]. Pregnant individuals (use only if the potential benefit justifies the potential risk to the fetus) [Source 1.5]. Breastfeeding individuals (use not recommended or caution should be exercised) [Source 1.4].
Populations for whom use is contraindicated	Patients with known hypersensitivity to hydrocortisone butyrate or any excipients [Source 1.1]; Patients with untreated viral infections (e.g., herpes simplex), fungal/yeast infections, parasitic infections, tubercular or syphilitic lesions, rosacea, acne vulgaris, and peri-oral dermatitis [Source 1.1].
Age-related eligibility rules	Indicated for patients 3 months of age and older [Source 1.2]; Infants and children may be more susceptible to systemic toxicity and require treatment to be limited in duration [Source 1.2, 2.7]; Older adults require no special dosage regimen [Source 1.1].

Eligibility classifications (high-level)

Category	Official Regulatory Statement
Eligibility severity classification	Contraindicated (Absolute prohibition due to infections/conditions); Not Established (Pediatric under 3 months); Restricted/Caution (Pregnancy, Lactation, Infants, Occlusion) [Source 1.2, 1.1].
Eligibility-context constraints	Use must avoid occlusive dressings (including tight-fitting diapers/plastic pants in infants) [Source 1.2]; Avoid use on the face, underarms, or groin areas unless directed by a healthcare provider [Source 1.3].

Resulting eligibility structure

Official regulatory documents define the eligibility profile by establishing clear contraindications that prohibit use for specific infections and hypersensitivity. The label permits use for patients 3 months of age and older, but places explicit restrictions and cautions for vulnerable groups like infants, pregnant individuals, and those using occlusive dressings due to the potential for systemic absorption. Furthermore, the product is prohibited for use on specific skin conditions such as rosacea or peri-oral dermatitis.

Interactions with other medicines and products — official regulatory information for Locoid Crelo (Hydrocortisone Butyrate)

---

Interaction scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Other corticosteroid-containing products (due to additive systemic exposure risk).
Specific interacting medicines (if explicitly listed)	None are explicitly listed by name in the product's official interaction sections.
Mechanistic basis of interactions (only if stated in label)	None specific to CYP enzymes or transporters are documented. The primary caution is based on a pharmacodynamic/exposure additive effect within the corticosteroid class.
Timing-based interaction rules (if applicable)	None documented. No mandatory separation of administration is specified in regulatory labels.

---

Interaction classifications (high-level)

Classification	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Specific drug–drug interactions are officially classified as "None known" or "No interaction studies have been performed." The additive exposure risk is classified as a Warning and Precaution.
Regulatory basis (EMA / FDA / etc.)	Information derived from FDA Prescribing Information and EMA/National Authority Summary of Product Characteristics (SmPC).

---

Resulting interaction structure

Statement Type	Official Regulatory Statement
Official interaction statements	• There are no known drug interactions documented with Locoid Crelo in its official prescribing information.
	• No interaction studies have been performed for Locoid Crelo.
	• The concomitant use of other corticosteroid-containing products may increase total systemic corticosteroid exposure due to additive effects, a risk that should be minimized.

Connection to the overall interaction profile: The regulatory documents establish that the official interaction profile for Locoid Crelo is characterized by the absence of documented specific drug–drug interactions (metabolic or transporter-mediated). The only explicit interaction-related constraint is a class-specific warning against the additive risk of systemic exposure when combining Locoid Crelo with other medicinal products containing corticosteroids, as mandated by regulatory authorities.

How Locoid Crelo Works

Modulating Inflammatory Gene Expression

Locoid Crelo's active ingredient, hydrocortisone butyrate, acts as an agonist for the cytosolic Glucocorticoid Receptor (GR) inside target cells. This binding initiates a cascade where the drug-receptor complex translocates to the nucleus, modifying the cell's gene expression profile. This action promotes the expression of genes that code for anti-inflammatory proteins while simultaneously repressing genes that produce pro-inflammatory mediators like certain cytokines. This genomic modulation results in a reduction of excessive signaling and the overall physiological effect is decreased cellular activity and reduced local immune response in the affected tissue.

Regulating Local Vascular and Cellular Dynamics

The drug also affects vascular dynamics and skin cell growth. It induces vasoconstriction, causing a narrowing of superficial blood vessels, which physically leads to a decrease in local blood flow to the application area. Additionally, it causes the inhibition of cell proliferation (anti-proliferative action) in certain hyper-proliferating skin cells. These complementary actions result in vasoconstriction and the inhibition of cell proliferation, contributing to altered tissue structure and thickness.

Official Administration Guidelines

Locoid Crelo, which contains hydrocortisone butyrate 0.1% in an emulsion/lotion form, is designated strictly for topical use (cutaneous application). The instructions define the specific manner in which the medicine is applied, the maximum treatment duration, and procedural constraints.

---

Administration Scope

Parameter	Official Instruction
Route of Administration	Topical (Cutaneous Use). Not for oral, ophthalmic, or intravaginal administration.
Dosing Schedule	Apply a thin layer to the affected skin areas. The dose is procedural, not a defined weight/volume.
Frequency and Timing	Apply two times daily. Therapy must be discontinued when control is achieved.
Age-Group Administration Rules	Approved for patients 3 months of age and older. Long-term use in pediatric patients should be avoided.
Course Duration	Safety and efficacy have not been established beyond four weeks of use. If no improvement is seen within two weeks, reassessment is necessary.

---

Procedural and Contextual Constraints

Classification	Instruction
Administration Method	Rub in gently after application.
Occlusion Restriction	Avoid use under occlusion (bandaging or wrapping) unless directed by a healthcare provider. Avoid use in the diaper area.
Restricted Body Areas	Do not use on the face, underarms, or groin areas unless directed by a healthcare provider.

---

Connection to the Overall Use Protocol

The standard use protocol is defined by a set of precise instructions that govern the short-term administration of the product. These instructions enforce a consistent topical route, a twice-daily application frequency, and strict limits on the duration of the course to four weeks. This framework ensures the medicine is used according to the procedural boundaries dictating both the how and the how long of the treatment.

Research Evidence / Overview of Studies for Locoid Crelo

The evidence base for the active ingredient in Locoid Crelo (hydrocortisone butyrate) is primarily derived from clinical trials, including randomized studies that compare the drug against an inactive substance. This overview explains what the research has explored and where limitations in the data may exist, consistent with findings reported in official scientific literature.

---

Evidence for use in Atopic Dermatitis

The main body of research for this condition was evaluated in short-term Randomized Controlled Trials (RCTs), where the active drug was compared against an inactive vehicle (placebo) or active comparator treatments. These studies were designed to explore how symptoms change over defined time intervals. Researchers monitored outcomes related to physical discomfort and inflammatory states in both adult and pediatric populations (starting at three months of age) with mild-to-moderate disease.

Short-term RCTs reported that the measured outcomes findings describe patterns observed in the studies when compared to the inactive vehicle. Research examined measurements of objective clinical signs such as redness and induration during the study period, and monitored how patient-reported outcomes, such as itching (pruritus), evolved over the treatment course.

What remains uncertain is how the measured outcomes change beyond the four-week timeframe. Long-term effects are not fully established, as most efficacy trials focused on short durations.

Evidence for use in Corticosteroid-Responsive Dermatoses

Locoid Crelo was studied for use in the broader category of corticosteroid-responsive skin conditions. Research examined outcomes linked to inflammatory or irritative states in adult subjects presenting with various forms of dermatitis. The evidence base includes controlled trials that compare the measured outcomes of the drug against other medium-potency topical steroids.

Vasoconstrictor assays were studied as a method for classifying the drug's properties. Research explored the application experience, with reports associated with subject ratings for cosmetic acceptability and ease of use.

However, follow-up durations were limited in most key efficacy trials. Data for certain groups remain insufficient, particularly for patients with severe disease or specific comorbid conditions not fully represented in the main trials. Research describes group patterns, not personal outcomes. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

1. LOCOID (hydrocortisone butyrate) emulsion: DailyMed Product Information (NIH)

Common questions about Locoid Crelo (FAQ)

Q: Is Locoid Crelo a strong steroid or a mild one?

Regulatory classification systems group topical corticosteroids based on their relative strength, or potency.

Official documents classify the 0.1% hydrocortisone butyrate formulation in Locoid Crelo as a medium-potency topical steroid. The strength is determined through laboratory testing that measures the drug's effect on narrowing blood vessels (vasoconstrictor assay).

---

Q: What is the difference between Locoid Crelo and regular Locoid cream?

The primary difference lies in the formulation base, often called the vehicle. Locoid Crelo is an emulsion/lotion formulation of hydrocortisone butyrate 0.1%.

Lotions are generally designed to be thinner and spread more easily over larger or hairy areas compared to a standard cream, which is typically thicker.

---

Q: Can Locoid Crelo be used on the face?

Official product information advises against applying the product to the face, groin, or underarm areas, unless use is specifically directed by a prescribing healthcare professional.

This restriction is in place because these sensitive areas are more prone to increased absorption and potential side effects.

---

Q: Is it safe to use Locoid Crelo for a long period of time?

The safety of Locoid Crelo has not been established in clinical studies for continuous use beyond a four-week period.

Official guidelines state that therapy should be discontinued as soon as the skin condition is controlled. Prolonged use can increase the potential for the medicine to be absorbed through the skin, which may lead to systemic effects like HPA axis suppression.

---

Q: Is Locoid Crelo the same as hydrocortisone?

Locoid Crelo contains the active ingredient hydrocortisone butyrate 0.1%.

Hydrocortisone is the base drug, and the 'butyrate' part indicates a modification made to the molecule (a specific ester) to create the active ingredient used in this product.

---

Q: Why is Locoid Crelo considered a topical corticosteroid?

The product is classified as a topical corticosteroid because its active ingredient, hydrocortisone butyrate, is a synthetic steroid.

Official sources note that this ingredient possesses the characteristic anti-inflammatory, anti-pruritic (anti-itching), and blood vessel-narrowing actions associated with this class of medication.

---

Q: Do you need a prescription for Locoid Crelo in most places?

Yes, formulations containing hydrocortisone butyrate 0.1%, such as Locoid Crelo, are typically classified as prescription-only medications (Rx Only) in the United States and many other regulatory regions.

---

Q: Are there different strengths of Locoid Crelo available?

Official regulatory labels indicate that the approved Locoid Crelo formulation is supplied in a single concentration.

This specific product formulation contains 0.1% hydrocortisone butyrate.

---

Q: Are there any specific areas of the body where Locoid Crelo should not be applied?

Official instructions specify that the product is strictly for cutaneous (skin) application and is not intended for use in the mouth, eyes (ophthalmic), or vagina (intravaginal).

Product information also advises against application to the face, groin, or underarms unless directed by a healthcare professional.

---

Q: Is Locoid Crelo a drug that can be absorbed systemically?

Yes, topically applied corticosteroids can be absorbed through the skin in sufficient amounts to potentially produce effects in other parts of the body (systemic effects).

Absorption can be increased by using the product for prolonged periods, over large areas of the body, or under occlusive dressings or wraps.

---

Q: What happens if Locoid Crelo is applied too often?

Applying the product more frequently than directed by a healthcare provider can increase the potential for systemic absorption.

This increase in absorption may lead to a higher risk of systemic side effects, such as the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis.

---

Q: Is Locoid Crelo commonly used for psoriasis?

As a medium-potency topical corticosteroid, this product is indicated for the inflammatory and itchy manifestations of corticosteroid-responsive skin conditions.

These generally include various forms of dermatitis, eczema, and mild to moderate psoriasis, though some regulatory sources note the exclusion of widespread plaque psoriasis.

---

Q: Can using Locoid Crelo cause the treated area to look lighter?

Yes, official product information reports that hypopigmentation (lightening of the skin color) is a local adverse reaction that has been associated with the use of this product.

This is a recognized change that can occur with topical corticosteroid use.

---

Q: What are the main risks that people need to be aware of when using this medicine?

The main systemic risk noted in regulatory documents is reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

This is a condition where the body's ability to produce certain hormones is temporarily affected. Localized risks include skin atrophy (thinning) and changes in skin color.

---

Q: Is Locoid Crelo known to cause irritation when first applied?

The product's regulatory label notes that local adverse reactions at the application site may occur.

These reactions commonly include sensations such as burning, stinging, itching, and general irritation.

---

Q: Can Locoid Crelo make my skin feel dry?

Yes, official safety information indicates that drying of the skin has been reported as a local adverse reaction associated with the use of the topical formulation.

---

Q: Does applying Locoid Crelo on large areas increase safety concerns?

Yes, using the product over a large body surface area is considered a condition that can augment (increase) systemic absorption.

Regulatory documents advise that patients who apply the product to a large area should be considered for periodic medical safety evaluations.

---

Q: What ingredients besides the active medicine are in Locoid Crelo?

Official regulatory labels include a list of inactive ingredients (excipients) that make up the formulation.

These typically include water, cetearyl alcohol, glycerin, various stabilizing agents, and preservatives like methylparaben.

---

Q: Why do official documents classify Locoid Crelo's strength the way they do?

Topical corticosteroid strength classification is based on measured vasoconstrictor potency.

This involves laboratory assays that measure the degree to which the medicine narrows blood vessels, which serves as a benchmark for its overall therapeutic strength.

---

Q: Does Locoid Crelo contain any common allergens?

Official safety information reports that allergic contact dermatitis, often evidenced by a failure of the treated condition to heal, may occur with topical corticosteroids.

For concerns about specific known allergens, patients are advised to consult the full list of inactive ingredients on the product label.

---

Q: If I miss an application, what do official sources say about the next steps?

Regulatory guidelines address missed applications by generally stating that if an application is forgotten, it is typically applied as soon as the patient remembers.

If it is nearly time for the next scheduled application, the patient information usually describes skipping the missed application. Instructions caution against applying more than one application at a time.

---

Q: What is the general difference between a 'lotion' and a 'crelo' formulation?

The term 'Crelo' is a specific brand name used for the 0.1% hydrocortisone butyrate lotion or emulsion formulation.

Lotions, in general pharmaceutical terms, are characterized by a lower viscosity (thinner consistency) compared to creams, making them suitable for widespread or hairy areas.

---

Q: Can Locoid Crelo be used under dressings or wraps?

Official administration instructions note that the product is generally not intended for use with occlusive dressings or wraps, or under a diaper.

This restriction is related to the increase in medicine absorption that occurs when the skin is covered, which raises the potential for systemic side effects.

---

Q: What does 'potential for systemic absorption' mean for Locoid Crelo users?

This means that the medicine, applied topically, can pass through the skin layers and enter the bloodstream.

If enough medicine is absorbed, it could potentially affect internal bodily systems, leading to systemic effects like HPA axis suppression or, very rarely, symptoms resembling Cushing's syndrome.

---

Q: Does Locoid Crelo help with itching or mainly inflammation?

Locoid Crelo, as a topical corticosteroid, is indicated for the relief of both the inflammatory and the pruritic (itching) signs of skin conditions that respond to corticosteroids.

Therefore, its effect is dual: reducing inflammation and providing relief from the associated itch.

Official Storage and Disposal Statements

Requirement	Official Regulatory Statement
Storage Temperature	Store at or below 25 C and keep from freezing.
Environmental Protection	Store in a closed container away from heat, moisture, and direct light.
Container Integrity	Keep the medicine in the original container until required.
Child Safety	Keep out of the sight and reach of children at all times.
Disposal Method	Do not use after the expiry date. Ask a pharmacist or healthcare professional for guidance on disposal.
Environmental Rule	Do not flush down a toilet or pour down a sink. If a take-back program is unavailable, mix with an undesirable substance and dispose of in household trash.

---

The regulatory profile requires the Locoid Crelo emulsion to be maintained in a cool dry place with temperature controls below 25 C, and protected from both freezing and light to ensure chemical stability. Disposal instructions mandate that the unused or expired product be discarded safely using approved methods, and explicitly prohibit disposal via wastewater.